Education
About Us
Working with TipRanks
Follow Us
Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
BTAI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.72 - $49.58
Previous CloseN/A
Volume1.10M
Average Volume (3M)9.23M
Market Cap
$6.98M
Enterprise Value$91.27M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.74
Next Earnings
May 12, 2025EPS Estimate
-2.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.91
Shares Outstanding3,290,192
10 Day Avg. Volume678,586
30 Day Avg. Volume9,229,421
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.18
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap13.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit40.28
Enterprise Value/Ebitda-1.63
Forecast
1Y Price Target
$48.50Price Target Upside2289.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalThe FDA feedback is seen as a plus, with the company advancing the BXCL501 trial readouts as key sentiment drivers.
Strategic DecisionsThe strategic decision to focus resources on clinical development and reduce commercial spending is a sound one.
Bears Say
Financial PerformanceSales reported were roughly $214K, well below the $1.2M that was previously forecasted.
Financial RisksCaution is advised in the near term given the company’s thinning cash position and rocky commercial uptake for Igalmi to date.
---
Ownership Overview
46.42% Insiders
4.16% Mutual Funds
0.10% Other Institutional Investors
46.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BTAI FAQ
What was Bioxcel Therapeutics Inc’s price range in the past 12 months?
Bioxcel Therapeutics Inc lowest stock price was $1.72 and its highest was $49.58 in the past 12 months.
What is Bioxcel Therapeutics Inc’s market cap?
Bioxcel Therapeutics Inc’s market cap is $6.98M.
When is Bioxcel Therapeutics Inc’s upcoming earnings report date?
Bioxcel Therapeutics Inc’s upcoming earnings report date is May 12, 2025 which is in 40 days.
How were Bioxcel Therapeutics Inc’s earnings last quarter?
Bioxcel Therapeutics Inc released its earnings results on Mar 27, 2025. The company reported -$3.57 earnings per share for the quarter, beating the consensus estimate of -$6.044 by $2.474.
Is Bioxcel Therapeutics Inc overvalued?
According to Wall Street analysts Bioxcel Therapeutics Inc’s price is currently Undervalued.
Does Bioxcel Therapeutics Inc pay dividends?
Bioxcel Therapeutics Inc does not currently pay dividends.
What is Bioxcel Therapeutics Inc’s EPS estimate?
Bioxcel Therapeutics Inc’s EPS estimate is -2.54.
How many shares outstanding does Bioxcel Therapeutics Inc have?
Bioxcel Therapeutics Inc has 3,290,192 shares outstanding.
What happened to Bioxcel Therapeutics Inc’s price movement after its last earnings report?
Bioxcel Therapeutics Inc reported an EPS of -$3.57 in its last earnings report, beating expectations of -$6.044. Following the earnings report the stock price went up 5.963%.
Which hedge fund is a major shareholder of Bioxcel Therapeutics Inc?
Among the largest hedge funds holding Bioxcel Therapeutics Inc’s share is Driehaus Capital Management LLC. It holds Bioxcel Therapeutics Inc’s shares valued at 0.
---
Bioxcel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$48.50 (2289.16% Upside)
$48.50 (2289.16% Upside)
Blogger Sentiment
Bullish
BTAI Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 19.5%
Last 30 Days ▲ 19.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.50%
12-Months-Change
Fundamentals
Return on Equity
82.91%
Trailing 12-Months
Asset Growth
-47.98%
Trailing 12-Months
Company Description
Bioxcel Therapeutics Inc
Bioxcel Therapeutics, Inc. (BTAI) is a biopharmaceutical company that leverages artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The company is focused on discovering, developing, and commercializing innovative therapies through its proprietary AI platform designed to identify new therapeutic opportunities. Their core areas include treatments for acute agitation in patients with neuropsychiatric disorders and therapies targeting rare forms of cancer.
---
BTAI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted progress in clinical trials and significant financial improvements, such as reduced net loss and increased revenue over the nine-month period. However, challenges remain with decreased quarterly revenue, increased costs, and uncertainties regarding cash runway and financing.Read More>---
BTAI Stock 12 Month Forecast
Average Price Target
$48.50
▲(2289.16% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Corcept Therapeutics
―
Intra-Cellular Therapies
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering BTAI
1 Year
1 Year Success Rate
12/40 ratings generated profit
1 Year Average Return
+33.05%
reiterated a buy rating 3 months ago
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of +33.05% per trade.
---